NEW YORK (GenomeWeb) – Genomic Health said today that it has signed a multi-year research collaboration agreement with Janssen Pharmaceuticals in which the companies will evaluate Genomic Health's Oncotype DX Genomic Prostate Score as a predictor of response to prostate cancer drugs in Janssen's pipeline.

Under the terms of the agreement, Genomic Health will test samples from studies Janssen is conducting to examine the association of GPS results with clinical outcomes.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Jun
05

This webinar will discuss how Sanofi used literature mining to annotate the association of human leukocyte antigen (HLA) alleles with diseases and drug hypersensitivity as part of a multiple sclerosis (MS) biomarker discovery project.

Jun
14

This webinar will discuss an effort underway at the University of North Carolina Medical Center's to overcome limitations in the hematological genomic testing workflow with artificial intelligence (AI) from Sophia Genetics.

Jun
19

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.

Jun
26

This webinar outlines a study that sought to characterize the landscape of alternative polyadenylation (APA) in the lung cancer transcriptome in order to gain insight into the role of APA in cancer progression.